Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rhythm Pharmaceuticals Inc.

62.71
-1.7000-2.64%
Pre-market: 60.13-2.5800-4.11%08:33 EDT
Volume:828.00K
Turnover:51.83M
Market Cap:3.99B
PE:-14.46
High:64.24
Open:63.30
Low:61.48
Close:64.41
Loading ...

Exploring High Growth Tech Stocks in January 2025

Simply Wall St.
·
23 Jan

Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

Subdued Growth No Barrier To Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Price

Simply Wall St.
·
19 Jan

Rhythm Pharmaceuticals price target raised to $60 from $58 at BofA

TIPRANKS
·
12 Jan

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)

TIPRANKS
·
11 Jan

TD Cowen Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
11 Jan

BRIEF-Rhythm Pharmaceuticals Imcivree Net Revenue FY24 Expected To Be About $130 Million

Reuters
·
10 Jan

Rhythm Pharmaceuticals Inc: Net REV FY24 Expected to Be About $130 Mln

THOMSON REUTERS
·
10 Jan

Rhythm Pharmaceuticals:on Track to Report Topline Data From Global Phase 3 Trial Evaluating Setmelanotide in Acquired Hypothalamic Obesity in H1 2025

THOMSON REUTERS
·
10 Jan

Rhythm Pharmaceuticals: Plan to Initiate New Phase 2 Trial Exploring Setmelanotide in Prader-Willi Syndrome

THOMSON REUTERS
·
10 Jan

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

GlobeNewswire
·
10 Jan

Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential

TipRanks
·
02 Jan

Jefferies Initiates Rhythm Pharmaceuticals at Buy With $80 Price Target

MT Newswires Live
·
02 Jan

Rhythm Pharmaceuticals initiated with a Buy at Jefferies

TIPRANKS
·
01 Jan

Exploring 3 High Growth Tech Stocks In The United States

Simply Wall St.
·
23 Dec 2024

Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years

Simply Wall St.
·
23 Dec 2024

Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Dow Jones
·
23 Dec 2024

FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children

Dow Jones
·
21 Dec 2024

Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use

MT Newswires Live
·
21 Dec 2024

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Benzinga
·
21 Dec 2024